Key result
CRT-P linked to ~54% higher mortality vs CRT-D, driven by non-sudden death.
Why the study?
Does CRT-P compared with CRT-D affect overall mortality and the specific causes of death in patients receiving cardiac resynchronization therapy?
Cohort (n=1,705)
Yes
Does CRT-P compared with CRT-D affect overall mortality and the specific causes of death in patients receiving cardiac resynchronization therapy?
Hazard Ratio: 1.54 (95% CI 1.07–2.21)
p-value: p=0.0209
The excess mortality observed in CRT-P recipients compared to CRT-D is predominantly driven by non-sudden death, suggesting that patients currently selected for CRT-P in routine practice would likely not benefit from the addition of a defibrillator.
No takes yet. Share an insight, caveat, or question.
CRT-P linked to excess non-sudden mortality versus CRT-D in this cohort; leaves open whether defibrillator addition improves outcomes in routine practice.
Marijon et al. (2015) conducted a cohort in Patients requiring cardiac resynchronization therapy (n=1,705). Cardiac resynchronization therapy without a defibrillator (CRT-P) vs. Cardiac resynchronization therapy with a defibrillator (CRT-D) was evaluated on Mortality (HR 1.54, 95% CI 1.07-2.21, p=0.0209). CRT-P was associated with increased mortality compared with CRT-D (HR 1.54; 95% CI 1.07-2.21; P=0.0209), with 95% of the excess mortality related to non-sudden death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: